Kenvue Inc. (NYSE:KVUE) Shares Sold by Freedom Investment Management Inc.

Freedom Investment Management Inc. lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 6.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,073 shares of the company’s stock after selling 1,245 shares during the quarter. Freedom Investment Management Inc.’s holdings in Kenvue were worth $395,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. RBO & Co. LLC grew its stake in Kenvue by 40.7% in the third quarter. RBO & Co. LLC now owns 991,419 shares of the company’s stock worth $22,932,000 after purchasing an additional 286,929 shares in the last quarter. Townsquare Capital LLC grew its position in shares of Kenvue by 25.3% in the 3rd quarter. Townsquare Capital LLC now owns 52,713 shares of the company’s stock worth $1,219,000 after acquiring an additional 10,629 shares in the last quarter. Brooklyn Investment Group bought a new stake in shares of Kenvue in the 3rd quarter valued at approximately $71,000. FMR LLC raised its position in shares of Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after acquiring an additional 3,075,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Kenvue by 5.5% during the third quarter. The Manufacturers Life Insurance Company now owns 2,138,576 shares of the company’s stock worth $49,465,000 after purchasing an additional 110,849 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.2 %

Shares of KVUE stock opened at $24.08 on Friday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The firm has a market capitalization of $46.17 billion, a PE ratio of 43.78, a price-to-earnings-growth ratio of 2.19 and a beta of 1.36. The stock has a fifty day moving average of $22.94 and a two-hundred day moving average of $20.99. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the prior year, the company posted $0.31 earnings per share. The company’s quarterly revenue was down .4% compared to the same quarter last year. As a group, research analysts expect that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.41%. Kenvue’s dividend payout ratio is presently 149.09%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KVUE. Bank of America boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Piper Sandler increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a research note on Tuesday, September 24th. Jefferies Financial Group began coverage on Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.